home/Home/Birth Control Pills Review/Nylia 1 / 35 Review

Nylia 1 / 35 Review

Nylia 1 / 35 is a monophasic low dose birth control pills prescribed as a means to protect a woman from an unwanted pregnancy.


Indications for use

Nylia 1 / 35 is intended for an oral contraception. The therapy of moderate acne and severe premenstrual syndrome (PMS) can be conducted by means of this birth control drug.

Mechanism of action

Nylia 1 / 35 belongs to a combined birth control drug. It is well-known due to anti-aldosterone and anti-androgenic quality factors. The main effect of this birth control includes the suppression of ovulation. It also alters the viscosity of cervical secretions. Such an effect prevent the spermatozoa from entering the uterine cavity. This drug may also reduce acne and pain during the premenstrual syndrome.

The Perl index is high in the case you take the medication correctly. If something wrong happens consult your doctor immediately.

Mode of application and dosage

Nylia 1 / 35 contains 21 active and 7 placebo pills. Every active pill should be taken at one and the same time to keep the hormone on the necessary level. The pill is washed down as a whole with a glass of water. The 2nd or the 3rd days will bring you menstruation. If it doesn’t happen, continue taking placebo pills and do a pregnancy test to exclude possible ramifications.


  • States precedenting thrombosis inclusively of transient ischemic attacks, angina pectoris which may be currently diagnosed or transferred prior in the medical history;
  • Defined acquired or genetic inclination to venous or arterial thrombosis inclusively of resistance to activated C protein, deficiency of antithrombin III, C protein deficiency, protein S deficiency, hyperhomocysteinemia, antibodies to phospholipids;
  • High risk or predisposition to venous or arterial thrombosis;
  • Venous and arterial thrombosis and thromboembolism diagnosed currently or in history inclusively of the following medical conditions: deep vein thrombosis, pulmonary artery thromboembolism, myocardial infarction, cerebrovascular disorders;
  • Migraine with focal neurological symptoms;
  • Diabetes with vascular complications;
  • Liver failure and severe liver disease including benign or malignant tumors;
  • Severe renal failure or acute renal failure;
  • Adrenal insufficiency;
  • Specified hormone-dependent malignant disorders;
  • Bleeding of unclear genesis;
  • Pregnancy: detected or suspected;
  • Breastfeeding;
  • Hypersensitivity to any of the components of the drug.

Side effects

Infectious and parasitic diseases:

  • infrequently – vaginitis/vulvovaginitis, vaginal candidiasis or other fungal vulvovaginal infections;
  • rarely – salpingo-oophoritis (adnexitis), urinary tract infections, cystitis, mastitis, cervicitis, fungal infections, candidiasis, herpetic oral cavity disease, influenza, bronchitis, sinusitis, upper respiratory infections, viral infection.

Benign, malignant and undefined neoplasms (including cysts and polyps): rarely – uterine fibroids, breast lipoma.

Hematopoietic system: rarely – sicle-cell anemia.

Immune system: rarely – allergic reactions like itching, hay fever, sneezing.

Endocrine system: rarely – virilism.

Metabolism and nutrition:

  • infrequently – increased appetite;
  • rarely anorexia.

Mental Disorders:

  • infrequently – decrease in mood;
  • rarely – depression, mental disorders, insomnia, sleep disorders, aggression;
  • frequency unknown – mood change, decreased libido, increased libido.

Nervous system:

  • often – headache;
  • infrequently – dizziness, migraine;
  • rarely – ischemic stroke, cerebrovascular disorders, dystonia.

Organ of vision:

  • rarely – dryness of the mucous membrane of the eyes, irritation of the mucous membrane of the eyes, oscillopsia, visual impairment;
  • frequency is unknown – intolerance to contact lenses.

Hearing and labyrinth disorders: rarely – sudden hearing loss, tinnitus, dizziness, hearing loss.

Cardiovascular system:

  • infrequently – increased blood pressure, decrease blood pressure;
  • rarely – cardiovascular disorders, tachycardia, venous and arterial thromboembolic complications, thrombophlebitis, diastolic hypertension, orthostatic circulatory dystonia, “hot flashes”, varicose veins, venous pathology.

Respiratory system: rarely – bronchial asthma, hyperventilation.

Gastrointestinal tract:

  • infrequently – abdominal pain, including pain in the upper and lower abdomen, discomfort/bloating, nausea, vomiting, diarrhea;
  • rarely – gastritis, enteritis, dyspepsia.

Skin and subcutaneous tissues:

  • infrequently – acne, alopecia, rash (including macular rash), pruritus (including generalized pruritus);
  • rarely, allergic dermatitis, atopic dermatitis/neurodermatitis, eczema, psoriasis, hyperhidrosis, chloasma, pigmentation disorder/hyperpigmentation, seborrhea, dandruff, hirsutism, skin pathology, skin reactions, orange peel, spider veins;
  • unknown frequency – urticaria, erythema nodosum, erythema multiforme.

Musculoskeletal system: rarely – back pain, discomfort in the muscles and skeleton, myalgia, pain in the limbs.

Genital organs and the mammary gland:

  • often – pain in the mammary glands, discomfort, tenderness of the mammary glands;
  • infrequently – changes in the quantity, duration and interval of menstrual bleeding;
  • rarely – cervical dysplasia, cysts of the uterus, pain in the area of the uterus, breast cyst, fibrocystic mastopathy, dyspareunia, galactorrhea, menstrual disorders;
  • unknown frequency – discharge from the mammary glands.

General disorders and disorders at the injection site:

  • infrequently – fatigue, asthenia, feeling unwell;
  • rarely – chest pain, peripheral edema, flu-like symptoms, inflammation, fever, irritability;
  • unknown frequency – fluid retention.

Impact on the results of laboratory and instrumental studies:

  • infrequently – changes in body weight (increase, decrease and fluctuations in body weight);
  • rarely – an increase in the concentration of triglycerides in the blood, hypercholesterolemia.


There is a possibility to combine drugs prescribed to induce hepatic microsomal enzymes resulting in the increase in the clearance of sex hormones. Such an increase can contribute to “breakthrough” uterine bleeding and/or to a decrease in the contraceptive effect.

Phenytoin, barbiturates, bosentan, primidone, carbamazepine, rifampicin and HIV treatment agents (ritonavir, nevirapine and efavirenz) and, possibly, oxcarbazepine, topiramate, felbamate, griseofulvin, as well as preparations containing St. John’s wort are agents devoted to increasing the clearance of the active substances.

When used together with this combination, many HIV protease or hepatitis C virus inhibitors and non-nucleoside reverse transcriptase inhibitors can either increase or decrease the concentration of estrogen or progestin in the blood plasma.

Consult your doctor to get to know more about the possible interactions of Nylia 1 / 35 with other preparations.

What if I miss a dose?

If the delay in taking the drug was less than 24 hours, contraceptive protection is not reduced. A woman should take the missed pill as soon as possible and take the next pill at the usual time.

If the delay in taking the pills is more than 24 hours, contraceptive protection can be reduced. The more missed pills and the closer the pill missing to the inactive placebo pill, the higher the chance of pregnancy is.

Nylia 1 / 35 and pregnancy

Nylia 1 / 35, like many other birth control drugs, is contraindicated during pregnancy and breastfeeding. The studies were conducted defining the possible influence on the fetus and newborn health. As a result of such surveys, it was revealed the chance to bring damage the fetus health is high. Moreover, there is a chance that hormones may enter breast milk.

Feedback Form

Review Content